Popular terms

[SEARCH]

Erythropoietin topics
Erythropoietin
Red Blood Cell
Recombinant
Nucleic Acid
Genetically
Regulatory Sequence
Endogenous
Peptide Sequence
Carbamylated
Ischemic Stroke
Therapeutical
Intracranial
Thrombopoietin
Leukemia Inhibitory Factor
Somatostatin

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Erythropoietin patents



      
           
This page is updated frequently with new Erythropoietin-related patent applications. Subscribe to the Erythropoietin RSS feed to automatically get the update: related Erythropoietin RSS feeds. RSS updates for this page: Erythropoietin RSS RSS



Date/App# patent app List of recent Erythropoietin-related patents
06/18/15
20150164991 
 Method and kit for evaluating and monitoring a treatment program for anemia patent thumbnailMethod and kit for evaluating and monitoring a treatment program for anemia
The present disclosure relates to methods and kits for evaluating and/or monitoring a treatment program, such as in an anemic subject or in a subject receiving treatment for anemia, including determining a presence or an amount of growth differentiation factor 15 (gdf15) and/or hepcidin in a biological sample from the subject. Further, in some embodiments, the disclosure provides methods and/or kits for treating a disorder of iron homeostasis in a subject, comprising measuring an amount of gdf15 and/or an amount of hepcidin in a sample from a subject and administering iron and/or erythropoietin (epo) to the subject if there is a measurable difference in the amount of gdf15 and/or hepcidin in the sample as compared to a reference amount..
Vanderbilt University


06/11/15
20150158924 
 Derivatisation of erythropoietin (epo) patent thumbnailDerivatisation of erythropoietin (epo)
The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..
Lipoxen Technologies Limited


06/04/15
20150152156 
 Tissue protective peptides and uses thereof patent thumbnailTissue protective peptides and uses thereof
The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
Araim Pharmaceuticals, Inc.


04/30/15
20150119325 
 Methods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues patent thumbnailMethods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues
The present invention provides methods for the high-level production of recombinant human erythropoietin (rhuepo) derivative, asialoerythropoietin (asialo-rhuepo), in plants. The methods for producing asialo-rhuepo comprise making a plant or at least one plant cell that comprises a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding a human erythropoieting fusion protein and a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding n-glycosylation modification enzyme, particularly a mammalian β1,4-galactosyltransferase.
North Carolina Central University


04/30/15
20150118187 
 Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof patent thumbnailMicro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a nucleic acid sequence operably linked to one or more regulatory sequences. The present invention is further directed to methods providing sustained expression of therapeutic polypeptides and prolonged therapeutic effects, such as erythropoietin and interferon..
Medgenics Medical Israel Ltd.


04/23/15
20150110743 
 Long lasting drug formulations patent thumbnailLong lasting drug formulations
The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.. .
Medgenics Medical Israel Ltd.


03/26/15
20150087695 
 Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo patent thumbnailTreatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
Oligonucleotide compounds modulate expression and/or function of erythropoietin (epo) polynucleotides and encoded products thereof. Methods for treating diseases associated with erythropoietin (epo) comprise administering one or more oligonucleotide compounds designed to inhibit the epo natural antisense transcript to patients..
Curna, Inc.


03/26/15
20150087065 
 Method for generation of conditionally immortalized hematopoietic progenitor cell lines with multiple lineage potential patent thumbnailMethod for generation of conditionally immortalized hematopoietic progenitor cell lines with multiple lineage potential
The present invention is a method and kits for generating a homogenous population of hematopoietic progenitor cells capable of differentiating into a hematopoietic cell lineage. Whereas the combination of homeobox-b8 protein and fms-like tyrosine kinase 3 ligand generate cells with the potential to differentiate into different myeloid and lymphoid cell types, homeobox-a7 protein and erythropoietin generate cells with the potential to differentiate into erythropoietic or thrombopoietic cell types..
St. Jude Children's Research Hospital


03/26/15
20150087060 
 Method for inducing erythropoietin-producing cell patent thumbnailMethod for inducing erythropoietin-producing cell
An object of the present invention is to provide a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells. The above object is achieved by providing a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells using a medium containing a specific growth factor and a specific compound..
Kyoto University


02/05/15
20150038403 
 Compounds that bind to the erythropoietin receptor patent thumbnailCompounds that bind to the erythropoietin receptor
The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin..

01/29/15
20150031696 

Cyanoisoquinoline compounds and methods of use thereof


The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:.
Fibrogen, Inc.


01/15/15
20150018274 

Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators


The present invention provides isolated stabilized epo-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized epo-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.. .
University Of Medicine And Dentistry Of New Jersey


01/08/15
20150011574 

(2-heteroarylamino) succinic acid derivatives


The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by the formula (1) wherein r1: an aromatic hydrocarbon ring group or an aromatic heterocyclic group; r2: a hydrogen atom, an alkyl group, or a heterocycloalkyl group; r3: a hydrogen atom or an alkyl group; a: a hydrogen atom or a hydroxy group; l: —nhco— or —och2—; and x: a nitrogen atom or ═ch—..
Daiichi Sankyo Company, Limited


01/08/15
20150011552 

4-alkanoylamino-3-pyrazolone derivative


The present invention provides a compound which enhances the production of erythropoietin. The present invention provides, for example, a compound represented by the formula (1) wherein r1: -q1, -q1-x-q2, or -q1-x-q2-y-q3: a monocyclic or bicyclic aromatic heterocyclic group; q2, q3: an aromatic hydrocarbon ring group or a monocyclic aromatic heterocyclic group; x: —conh—, —conhch2—, —ch2och2—, —nhch2ch2—, or the like; y: a single bond, —o—, —(ch2)n—, or —o—(ch2)n—; m, n: an integer from 1 to 3; r2: h or an alkyl group; and r3: h, an alkoxycarbonyl group, a carboxy group, an aromatic hydrocarbon ring group, or a monocyclic aromatic heterocyclic group..
Daiichi Sankyo Company, Limited


12/25/14
20140378378 

Erythropoietin-derived peptide and use therefor


Provided are a peptide, which has an amino acid sequence of seq id no. 1 and is effective for the prevention of cell damage, and a pharmaceutical composition for preventing cell damage, the pharmaceutical composition including the peptide as an active component.

11/20/14
20140343094 

Novel nitrogen-containing heteroaryl compounds and methods of use thereof


The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.. .

10/30/14
20140323401 

Tissue protective peptides and uses thereof


The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.

10/23/14
20140315802 

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..

10/16/14
20140309407 

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..

10/16/14
20140309166 

Derivatisation of erythropoietin (epo)


The present invention relates to a compound which is a polysaccharide derivative of epo, or of an epo like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds..

10/02/14
20140296318 

Novel tissue protective erythropoietin receptor (nepor) and methods of use


Methods of determining whether a patient is suitable for erythropoietin (epo) therapy, including (a) isolating a tissue sample from said patient; (b) determining the level of expression of eph-b4 in said sample; and (c) correlating a presence of eph-b4 expression to a negative physiological response to epo therapy). In addition, methods of enhancing the effectiveness of epo therapy in a patient by administering to said patient, in conjunction with epo therapy, an sirna specific for eph-b4..

10/02/14
20140296175 

Composition and inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell


A composition for inducing erythropoietin (epo)-mediated haemoglobin (hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (i), wherein r is a glycosyl group; and a pharmaceutical acceptable carrier..

09/25/14
20140288172 

Erythropoietin production-promoting agent


A therapeutic and/or prophylactic agent for renal anemia comprising alas and an erythropoietin production promoter comprising alas.. .

09/11/14
20140255337 

Methods of treating cognitive impairment


The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (flt3) ligand, interleukin-6 (il-6), macrophage migration inhibitory factor (mif), interleukin-1 (il-1), interleukin-3 (il-3), erythropoietin (epo), vascular endothelial growth factor a (vegf-a), hypoxia-inducible transcription factor (hif-1alpha), insulin like growth factor-1 (igf-1), tumor necrosis factor (tnf), granulocyte colony-stimulating factor (g-csf), granulocyte/macrophage colony-stimulating factor (gm-csf), macrophage colony-stimulating factor (m-csf), stem cell factor (scf), darbepoetin (aranesp), and metalloproteinases, to an animal or person in need of treatment..

08/28/14
20140243510 

Methods for purifying erythropoietin analogs having lower isoelectric point


The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an n-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost..

08/28/14
20140243324 

Use of hematopoietic growth factor mimetics


The present invention relates to uses of small molecule mimetics of hematopoietic growth factors. In particular the present invention relates to uses of small molecule mimetics of erythropoietin..

08/07/14
20140216950 

Erythropoietin receptor modified electrode and its preparation method and application


The invention discloses an erythropoietin receptor modified electrode, which is a glassy carbon electrode with erythropoietin receptor as recognition element fixed onto the electrode surface via zno sol-gel. The modified electrode can be prepared easily, and its performance is stable.

07/17/14
20140200180 

Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens


Methods for producing proteins and glycoproteins in pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant pichia pastoris strains that do not display a β-mannosyltransferase 2 activity with respect to an n-glycan or o-glycan and do not display at least one activity selected from a β-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins.

06/26/14
20140178335 

Use of il-12 to generate endogenous erythropoietin


The present invention relates to the use of exogenous interleukin-12 (il-12) for increasing endogenous production of erythropoietin.. .

06/12/14
20140163207 

Method for purifying pegylated erythropoietin


Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange sp sephacryl™ s 500 hr chromatography material conditioned to a conductivity of 21 ms/cm and a linear gradient elution a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield..

06/12/14
20140161766 

Tetrameric cytokines with improved biological activity


The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety.

06/05/14
20140154205 

Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications


A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of erythropoietin and about 100-300 mg per cm2 wound tissue of fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject.

05/22/14
20140142122 

Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival


Disclosed herein are erythropoietin-mimetic compounds of formula i, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor.

05/08/14
20140128472 

Treatment and prevention of diseases related to oxidative stress


The present invention relates to the field of treatment and prevention of conditions related to oxidative stress and hormone resistance. Preferably, insulin resistance, erythropoietin resistance and acetyl-choline resistance are in the focus.

05/01/14
20140120100 

Compositions and methods for preventing erythropoietin-associated hypertension


The inventors have discovered that both soluble erythropoietin-binding protein and antibodies against the erythropoietin-binding protein, when they are administered to a mammal along with erythropoietin (epo), prevent or reduce the blood pressure increase normally caused by erythropoietin, while not affecting the hematocrit increase that is the purpose of epo treatment. The invention provides a method of treating anemia in a mammal involving: administering erythropoietin (epo) to the mammal; and administering to the mammal an agent selected from a soluble epo-binding protein (epo-bp), a recognition protein that binds epo receptor on an extracellular soluble portion of the epo receptor, and a combination thereof.

02/20/14
20140053288 

Epo knockout gfp anemic mouse


The present invention relates to a model animal spontaneously developing anemia. More specifically, the invention relates to a transgenic non-human mammal spontaneously developing anemia associated with a postnatal decrease in production of erythropoietin (epo), epo-producing cells prepared from the transgenic non-human mammal, and a screening method using the epo-producing cells..

02/13/14
20140045748 

Composition for aiding surgical procedures for treating ischemic vascular diseases


The present invention relates to a composition comprising erythropoietin (epo) as an active ingredient for aiding surgical procedures for treating ischemic vascular diseases. The present invention also relates to a method for treating ischemic vascular diseases using said composition.

01/23/14
20140024699 

Compositions and methods for increasing erythropoietin (epo) production


The invention relates to double-stranded ribonucleic acid (dsrna) compositions targeting one or more egln genes, egln1, egln2 and/or egln3 and methods of using such dsrna compositions to inhibit expression of these genes.. .

01/16/14
20140017305 

Encapsulated liver cell composition


Microcapsules including a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact with a liver cell stimulating amount of erythropoietin.. .

01/09/14
20140011740 

Modified animal erythropoietin polypeptides and their uses


Modified animal erythropoietin polypeptides and uses thereof are provided.. .

01/02/14
20140005109 

Therapeutic compositions and methods for disorders associated with neuronal degeneration


Disclosed are isolated mutant erythropoietin (epo) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant epo peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76.

12/26/13
20130345158 

Composition for promoting hematogenesis containing quercetin 3-o-beta-(2''-galloyl)-rhamnopyranoside as active ingredient


This invention relates to a composition for promoting hematopoiesis and for treating, preventing or alleviating cytopenia or bone marrow failure comprising quercetin 3-o-β-(2″-galloyl)-rhamnopyranoside (qgr) as active ingredient. The present active compound qgr (i) increases dose dependently the mrna expression of cytokines involved in hematopoiesis including stem cell factor, granulocyte-macrophage colony stimulating factor and erythropoietin from mouse bone marrow mononuclear cells, (ii) promotes the formation of burst forming unit-erythroid and colony forming unit-fibroblast, (iii) stimulates the generation of cells positive for ter-119, a specific marker of mouse erythroid precursors, (iv) promotes erythropoiesis, leukopoiesis, thrombopoiesis, and hemoglobin production in bone marrow failure mouse model, (v) stimulates the formation of hematopoietic stem/progenitor cells and mesenchymal stem/progenitor cells, (vi) stimulates megakaryocyte formation surrounding the blood system of damaged bone marrow, osteoid formation and bone marrow restoration through a recovery of damaged bone marrow microenvironment.

12/26/13
20130344497 

Use of novel cytokine receptors as biomarkers and therapeutic targets in human cancer


Nucleic acids encoding erythropoietin isoforms are described herein, as well as the encoded isoforms, methods of detecting the same, and methods of screening for and treating cancer.. .

12/26/13
20130344032 

Method of treating anemia caused by ribavirin treatment of hepatitis c using erythropoietin alpha


Claimed and disclosed is a new use for a previously approved drug: erythropoietin. The present invention teaches using erythropoetin to treat anemia caused by the combined treatment of ribavirin and alpha-interferon.

12/05/13
20130323774 

Homogenous and fully glycosylated human erythropoietin


The present invention provides homogenous, fully-glycosylated, full length erythropoietin and the methods of producing the same.. .

11/28/13
20130316967 

Compounds and methods for enhancing erythropoiesis


Compounds and methods for enhancing erythropoiesis. The compound contains a chemical structure of the formula (i) indicated below, in which r is a glucosyl group.

11/21/13
20130310565 

Novel nitrogen-containing heteroaryl compounds and methods of use thereof


The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.. .

11/07/13
20130295113 

Anti-erythropoietin antibodies


The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies..



Popular terms: [SEARCH]

Erythropoietin topics: Erythropoietin, Red Blood Cell, Recombinant, Nucleic Acid, Genetically, Regulatory Sequence, Endogenous, Peptide Sequence, Carbamylated, Ischemic Stroke, Therapeutical, Intracranial, Thrombopoietin, Leukemia Inhibitory Factor, Somatostatin

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Erythropoietin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Erythropoietin with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2579

5134

1 - 1 - 102